ARA?290, also termed cibinetide or pHBSP, originates from the helix?B surface motif of erythropoietin. Protein?engineering design separates two distinct biological functions of native EPO: it selectively triggers signalling via the innate repair receptor heterocomplex, while leaving aside erythropoietic activity driven by classic EPOR homodimer. This functional partition avoids erythrocyte?proliferating effects, which constitutes its core value for experimental neuropathology and tissue?injury explorationexcaliburp....

A pyroglutamate ring at the N?terminus forms an intrinsic structural feature, which stabilizes the peptide backbone against aminopeptidase cleavage. Quality assessment must confirm full cyclization status of the terminal residue; incomplete cyclization represents a major process?related impurity. Mass spectrometry distinguishes cyclic pyro?glutamate form from linear precursor variants, and chromatographic profiling removes truncated peptide fragments before batch release. Research scenarios mainly cover small?fiber neuropathy models, local anti?inflammatory response observation, ischaemia?reperfusion damage assays and peripheral nerve?repair mechanistic studies.

The peptide maintains good stability in lyophilised form under frozen sealed storage. When preparing experimental stock solutions, neutral?pH buffer conditions are preferred. Although N?terminal cyclization offers partial enzymatic resistance, dissolved samples remain vulnerable to carboxypeptidase?mediated C?terminal hydrolysis. Divide reconstituted liquid into single?use aliquots. Minimize repeated freeze?thaw events to preserve sequence integrity and reproducible receptor?response readouts.